About Vigil Neuroscience, Inc. - Common Stock (VIGL)
Vigil Neuroscience, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly those that affect aging populations. The company leverages cutting-edge research and technology to identify and target underlying mechanisms of these conditions, with an emphasis on harnessing the body’s immune system. By designing treatments that specifically address the progression of neurodegeneration, Vigil aims to improve patient outcomes and enhance quality of life for individuals suffering from diseases such as Alzheimer's and other related disorders. Through its commitment to advancing scientific understanding and therapeutic options in neuroscience, Vigil is positioned at the forefront of addressing critical unmet medical needs within the field. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash (payable following the first commercial sale of VG-3927 if achieved within a specific period). KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
A wave of high-impact announcements is fueling explosive momentum across tech and healthcare stocks. From AI infrastructure to biotech M&A and consumer health expansion, investors are turning to breakout companies under $10 poised for rapid upside.
The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.
Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3 2025. VG-3927 showed promise in Phase 1 for Alzheimer's treatment.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Vigil Neuroscience, Inc. (NASDAQ: VIGL) to Sanofi is fair to Vigil shareholders. Under the terms of the proposed transaction, Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period.
- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 -
- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) -
– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer’s Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 –
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Wednesday, March 19, 2025, at 9:00 a.m. ET.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
